title: Effect of a selective OX1R antagonist on food intake and body weight in two strains of rats that differ in susceptibility to dietary-induced obesity.
abstract: An orexin-1 receptor antagonist decreases food intake whereas orexin-A selectively induces hyperphagia to a high-fat diet. In the present study, we evaluated the effect of an orexin antagonist in two strains of rats that differ in their sensitivity to becoming obese while eating a high-fat diet. Male Osborne-Mendel (OM) and S5B/Pl (S5B) rats were treated acutely with an orexin-1 receptor antagonist (SB-334867), after adaptation to either a high-fat (56% fat energy) diet or a low-fat (10% fat energy) diet that were equicaloric for protein (24% energy). Ad libitum fed rats were injected intraperitoneally with SB-334867 at doses of 3, 10 or 30 mg/kg, or vehicle at the beginning of the dark cycle, and food intake and body weight were measured. Hypothalamic prepro-orexin and orexin-1 receptor mRNA expression were analyzed in OM and S5B rats fed at a high-fat or low-fat diet for two weeks. SB-334867 significantly decreased food intake in both strains of rats eating the high-fat diet but only in the OM rats eating the low fat diet. The effect was greatest at 12 and 24 h. Body weight was also reduced in OM rats 1d after injection of SB-334867 but not in the S5B rats. Prepro-orexin and orexin-1 receptor expression levels did not differ between strains or diets. These experiments demonstrate that an orexin antagonist (SB-334867) reduces food intake and has a greater effect in a rat strain that is susceptible to dietary-induced obesity, than in a resistant strain.
authors.affiliation: Pennington Biomedical Research Center, Experimental Obesity laboratory, Louisiana State University System, 6400 Perkins Road, Baton Rouge, LA 70808, USA. whitecl@pbrc.edu
authors.forename: C L
authors.initials: CL
authors.lastname: White
authors.forename: Y
authors.initials: Y
authors.lastname: Ishii
authors.forename: T
authors.initials: T
authors.lastname: Mendoza
authors.forename: N
authors.initials: N
authors.lastname: Upton
authors.forename: L P
authors.initials: LP
authors.lastname: Stasi
authors.forename: G A
authors.initials: GA
authors.lastname: Bray
authors.forename: D A
authors.initials: DA
authors.lastname: York
mesh_terms: D000818:Animals; D001583:Benzoxazoles / Q000008:administration & dosage*; D001835:Body Weight / Q000187:drug effects*; D004032:Diet / Q000009:adverse effects*; D004435:Eating / Q000187:drug effects*; D005786:Gene Expression Regulation / Q000187:drug effects; D007031:Hypothalamus / Q000378:metabolism*; D008297:Male; D009287:Naphthyridines; D009765:Obesity / Q000378:metabolism*; D064446:Orexin Receptors; D011498:Protein Precursors / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D043562:Receptors, G-Protein-Coupled; D018013:Receptors, Neuropeptide / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D013045:Species Specificity; D014508:Urea / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: C420062:1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea; D001583:Benzoxazoles; C578627:Hcrtr1 protein, rat; D009287:Naphthyridines; D064446:Orexin Receptors; D011498:Protein Precursors; D012333:RNA, Messenger; D043562:Receptors, G-Protein-Coupled; D018013:Receptors, Neuropeptide; D014508:Urea